Global PEGylated Drugs 麻豆原创 Research Report 2023

Publication ID:

PB510235479

Publication Date:

October 31, 2023

Pages:

103

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Healthcare [2]

Pharma & Healthcare [3]

Description:

The global PEGylated Drugs market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global PEGylated Drugs market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
AstraZeneca
Bayer Healthcare
Biogen
BioMarin Pharmaceutical Inc
Coherus BioSciences
Enzon
Horizon Therapeutics
Leadiant Biosciences, Inc.
Merck
Mylan
Novo Nordisk
Pfizer
Roche
Sandoz
Servier Pharmaceuticals LLC
Takeda Pharmaceutical Company Limited
Segment by Type
Macromolecular Drugs
Small Molecular Drugs
Nanoparticles
Segment by Application
Cancer
Hepatitis C
Leukemia
Severe Combined Immunodeficiency Disease
Rheumatoid Arthritis
Crohn Disease
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The PEGylated Drugs report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global PEGylated Drugs 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Macromolecular Drugs
1.2.3 Small Molecular Drugs
1.2.4 Nanoparticles
1.3 麻豆原创 by Application
1.3.1 Global PEGylated Drugs 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Cancer
1.3.3 Hepatitis C
1.3.4 Leukemia
1.3.5 Severe Combined Immunodeficiency Disease
1.3.6 Rheumatoid Arthritis
1.3.7 Crohn Disease
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global PEGylated Drugs 麻豆原创 Perspective (2018-2029)
2.2 PEGylated Drugs Growth Trends by Region
2.2.1 Global PEGylated Drugs 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 PEGylated Drugs Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 PEGylated Drugs Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 PEGylated Drugs 麻豆原创 Dynamics
2.3.1 PEGylated Drugs Industry Trends
2.3.2 PEGylated Drugs 麻豆原创 Drivers
2.3.3 PEGylated Drugs 麻豆原创 Challenges
2.3.4 PEGylated Drugs 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top PEGylated Drugs Players by Revenue
3.1.1 Global Top PEGylated Drugs Players by Revenue (2018-2023)
3.1.2 Global PEGylated Drugs Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global PEGylated Drugs 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by PEGylated Drugs Revenue
3.4 Global PEGylated Drugs 麻豆原创 Concentration Ratio
3.4.1 Global PEGylated Drugs 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PEGylated Drugs Revenue in 2022
3.5 PEGylated Drugs Key Players Head office and Area Served
3.6 Key Players PEGylated Drugs Product Solution and Service
3.7 Date of Enter into PEGylated Drugs 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 PEGylated Drugs Breakdown Data by Type
4.1 Global PEGylated Drugs Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global PEGylated Drugs Forecasted 麻豆原创 Size by Type (2024-2029)
5 PEGylated Drugs Breakdown Data by Application
5.1 Global PEGylated Drugs Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global PEGylated Drugs Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America PEGylated Drugs 麻豆原创 Size (2018-2029)
6.2 North America PEGylated Drugs 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America PEGylated Drugs 麻豆原创 Size by Country (2018-2023)
6.4 North America PEGylated Drugs 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe PEGylated Drugs 麻豆原创 Size (2018-2029)
7.2 Europe PEGylated Drugs 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe PEGylated Drugs 麻豆原创 Size by Country (2018-2023)
7.4 Europe PEGylated Drugs 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific PEGylated Drugs 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific PEGylated Drugs 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific PEGylated Drugs 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific PEGylated Drugs 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America PEGylated Drugs 麻豆原创 Size (2018-2029)
9.2 Latin America PEGylated Drugs 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America PEGylated Drugs 麻豆原创 Size by Country (2018-2023)
9.4 Latin America PEGylated Drugs 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa PEGylated Drugs 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa PEGylated Drugs 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa PEGylated Drugs 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa PEGylated Drugs 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca PEGylated Drugs Introduction
11.1.4 AstraZeneca Revenue in PEGylated Drugs Business (2018-2023)
11.1.5 AstraZeneca Recent Development
11.2 Bayer Healthcare
11.2.1 Bayer Healthcare Company Detail
11.2.2 Bayer Healthcare Business Overview
11.2.3 Bayer Healthcare PEGylated Drugs Introduction
11.2.4 Bayer Healthcare Revenue in PEGylated Drugs Business (2018-2023)
11.2.5 Bayer Healthcare Recent Development
11.3 Biogen
11.3.1 Biogen Company Detail
11.3.2 Biogen Business Overview
11.3.3 Biogen PEGylated Drugs Introduction
11.3.4 Biogen Revenue in PEGylated Drugs Business (2018-2023)
11.3.5 Biogen Recent Development
11.4 BioMarin Pharmaceutical Inc
11.4.1 BioMarin Pharmaceutical Inc Company Detail
11.4.2 BioMarin Pharmaceutical Inc Business Overview
11.4.3 BioMarin Pharmaceutical Inc PEGylated Drugs Introduction
11.4.4 BioMarin Pharmaceutical Inc Revenue in PEGylated Drugs Business (2018-2023)
11.4.5 BioMarin Pharmaceutical Inc Recent Development
11.5 Coherus BioSciences
11.5.1 Coherus BioSciences Company Detail
11.5.2 Coherus BioSciences Business Overview
11.5.3 Coherus BioSciences PEGylated Drugs Introduction
11.5.4 Coherus BioSciences Revenue in PEGylated Drugs Business (2018-2023)
11.5.5 Coherus BioSciences Recent Development
11.6 Enzon
11.6.1 Enzon Company Detail
11.6.2 Enzon Business Overview
11.6.3 Enzon PEGylated Drugs Introduction
11.6.4 Enzon Revenue in PEGylated Drugs Business (2018-2023)
11.6.5 Enzon Recent Development
11.7 Horizon Therapeutics
11.7.1 Horizon Therapeutics Company Detail
11.7.2 Horizon Therapeutics Business Overview
11.7.3 Horizon Therapeutics PEGylated Drugs Introduction
11.7.4 Horizon Therapeutics Revenue in PEGylated Drugs Business (2018-2023)
11.7.5 Horizon Therapeutics Recent Development
11.8 Leadiant Biosciences, Inc.
11.8.1 Leadiant Biosciences, Inc. Company Detail
11.8.2 Leadiant Biosciences, Inc. Business Overview
11.8.3 Leadiant Biosciences, Inc. PEGylated Drugs Introduction
11.8.4 Leadiant Biosciences, Inc. Revenue in PEGylated Drugs Business (2018-2023)
11.8.5 Leadiant Biosciences, Inc. Recent Development
11.9 Merck
11.9.1 Merck Company Detail
11.9.2 Merck Business Overview
11.9.3 Merck PEGylated Drugs Introduction
11.9.4 Merck Revenue in PEGylated Drugs Business (2018-2023)
11.9.5 Merck Recent Development
11.10 Mylan
11.10.1 Mylan Company Detail
11.10.2 Mylan Business Overview
11.10.3 Mylan PEGylated Drugs Introduction
11.10.4 Mylan Revenue in PEGylated Drugs Business (2018-2023)
11.10.5 Mylan Recent Development
11.11 Novo Nordisk
11.11.1 Novo Nordisk Company Detail
11.11.2 Novo Nordisk Business Overview
11.11.3 Novo Nordisk PEGylated Drugs Introduction
11.11.4 Novo Nordisk Revenue in PEGylated Drugs Business (2018-2023)
11.11.5 Novo Nordisk Recent Development
11.12 Pfizer
11.12.1 Pfizer Company Detail
11.12.2 Pfizer Business Overview
11.12.3 Pfizer PEGylated Drugs Introduction
11.12.4 Pfizer Revenue in PEGylated Drugs Business (2018-2023)
11.12.5 Pfizer Recent Development
11.13 Roche
11.13.1 Roche Company Detail
11.13.2 Roche Business Overview
11.13.3 Roche PEGylated Drugs Introduction
11.13.4 Roche Revenue in PEGylated Drugs Business (2018-2023)
11.13.5 Roche Recent Development
11.14 Sandoz
11.14.1 Sandoz Company Detail
11.14.2 Sandoz Business Overview
11.14.3 Sandoz PEGylated Drugs Introduction
11.14.4 Sandoz Revenue in PEGylated Drugs Business (2018-2023)
11.14.5 Sandoz Recent Development
11.15 Servier Pharmaceuticals LLC
11.15.1 Servier Pharmaceuticals LLC Company Detail
11.15.2 Servier Pharmaceuticals LLC Business Overview
11.15.3 Servier Pharmaceuticals LLC PEGylated Drugs Introduction
11.15.4 Servier Pharmaceuticals LLC Revenue in PEGylated Drugs Business (2018-2023)
11.15.5 Servier Pharmaceuticals LLC Recent Development
11.16 Takeda Pharmaceutical Company Limited
11.16.1 Takeda Pharmaceutical Company Limited Company Detail
11.16.2 Takeda Pharmaceutical Company Limited Business Overview
11.16.3 Takeda Pharmaceutical Company Limited PEGylated Drugs Introduction
11.16.4 Takeda Pharmaceutical Company Limited Revenue in PEGylated Drugs Business (2018-2023)
11.16.5 Takeda Pharmaceutical Company Limited Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

AstraZeneca
Bayer Healthcare
Biogen
BioMarin Pharmaceutical Inc
Coherus BioSciences
Enzon
Horizon Therapeutics
Leadiant Biosciences, Inc.
Merck
Mylan
Novo Nordisk
Pfizer
Roche
Sandoz
Servier Pharmaceuticals LLC
Takeda Pharmaceutical Company Limited

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.